STRO Sutro Biopharma, Inc.
Distress ·
Sutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs.
Sutro has until December 17, 2025 to bring its share price back above $1.00 for ten consecutive business days, or face a delisting process. The company says it plans a reverse stock split before that date if necessary, and its 10-K shows three partners that ended clinical work after Phase 1.
Sutro will deprioritize luvelta, exit its manufacturing facility and cut about 50% of staff, with costs of $40 million to $45 million. Jane Chung succeeds William J. Newell as CEO. Cash was $316.9 million at year-end.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $166.4 million | $252.0 million |
| Net income (loss) | -$191.1 million | -$227.5 million |
| Cash from operations | -$177.2 million | -$191.5 million |
| Cash and equivalents | $58.1 million | $190.3 million |
| Short-term investments | $83.3 million | $126.6 million |
Opinion Negative view
Sutro had $164.3 million at June 30, 2026, and burned $36.3 million a quarter on average. Management says that lasts at least 12 months. We think another raise comes before the cash runs out.
Our latest story on this, dated Jun 25, 2025: "Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 25, 2025: "Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jun 25, 2025: "Sutro Biopharma receives Nasdaq notice for falling below $1.00 bid price". The story links the filing or release it is based on. Read the story.
Sutro Biopharma, Inc. trades under the ticker STRO on NASDAQ.
Sutro Biopharma, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:S090.
The SEC Central Index Key (CIK) for Sutro Biopharma, Inc. is 1382101. Its filings are on SEC EDGAR.
16,581,171 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-12.
Our directory records Sutro Biopharma, Inc. under United States.
Our directory classifies Sutro Biopharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Sutro Biopharma, Inc. is US8693672011.
aibio.space lists Sutro Biopharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Sutro Biopharma, Inc. reported a net loss of $191.1 million for the fiscal year ended Dec 31, 2025, and used $177.2 million of cash in operations, per its annual report to the SEC.
$166.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
$164.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Sutro Biopharma, dated Sep 29, 2025: "Sutro Biopharma plans to cut workforce by about one-third, expects cash runway into mid-2027". Sutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs. Source.
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.02,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,2.05,5.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio